Alembic Pharmaceuticals share news, announcements and annual reports
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Alembic Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2011
Last close ₹797.85up ₹3.00 (0.38%)BSE ₹797.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹794.85.
30 Oct: open ₹794.85, high ₹800.00, low ₹784.05
52-week range of traded prices to 30 Oct 2026
₹635.80Low, 23 Mar 2026₹998.00High, 4 Nov 2025
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,683 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.69
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.50%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 72,86569.4% delivered
Alembic Pharmaceuticals share news and announcements
971 announcements, routine notices left out, newest first. Page 9 of 20.
Sep 2022
1 Sep · Disclosure of other UPSI/material event
Aug 2022
29 Aug · Disclosure of other UPSI/material event
8 Aug · Analysts
2 Aug · Analysts
Jul 2022
27 Jul · Corporate action
27 Jul · Analysts
Jun 2022
22 Jun · General updates
17 Jun · General updates
15 Jun · NCLT/ Court Convened Meeting
15 Jun · NCLT/ Court Convened Meeting
15 Jun · NCLT/ Court Convened Meeting
May 2022
16 May · Related Party Transaction
13 May · Analysts
10 May · NCLT/ Court Convened Meeting
2 May · Results
Apr 2022
28 Apr · Analysts
21 Apr · Analysts
7 Apr · General updates
6 Apr · General updates
Mar 2022
29 Mar · Legal
Exchange has sought clarification from Alembic Pharmaceuticals Limited with respect to announcement dated 29-Mar-2022 informing about Acquisition.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Cost of acquisition or the price at which the shares are acquired; The response of the company is awaited.